Skip to main content
OpenTrials
Completed

NCT Number: NCT03133741

Inhibition of the Endogenous GIP Response With a GIP Receptor Antagonist

Delinieation of GIP's effects during an oral glucose tolerance test (OGTT) in humans using GIP receptor antagonisation.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year–70 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Center for Diabetes Research

Gentofte Municipality, Copenhagen, 2900, Denmark

About this study

Aim: To evaluate the role of GIPR signalling in postprandial physiology, including bone and glucose homeostasis, using a naturally occurring GIP fragment (GIP-A), which antagonises the GIPR.

Eighteen healthy men (age 18-70 years, BMI 19-35 kg/m2) with normal kidney and liver parameters and haemoglobin levels and no first-degree relatives with type 2 diabetes will be included in a randomised, double-blinded, placebo-controlled cross-over study. Study consists of four study days with concomitant infusions of A) GIP-A, B) GLP-1 receptor antagonist Exendin[9-39], C) GIP-A + Exendin[9-39], or D) saline (placebo).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Normal kidney function, liver function and hemoglobin levels.

Exclusion criteria

  • Medication, Diabetes type 1 or 2, first degree relatives with Diabetes type 2

Treatment and study plan

GIP-A

Other

GIP-A (GIP receptor antagonist)

GLP-1 receptor antagonist Exendin[9-39]

Other

Exendin[9-39]

Other names: EX(9-39)

Placebo

Other

Saline (9mg/mL)

Other names: Saline

GIP-A + Exendin[9-39]

Other

GIP receptor antagonist + GLP-1 receptor antagonist

Primary outcomes

  1. Insulin levels

    Time frame: 240 minutes

    Serum insulin AUC (area under the curve)

Sponsors and collaborators

Lead sponsor

University Hospital, Gentofte, Copenhagen

Other

Collaborators

  • University of Copenhagen

Registry information

Official study title

Inhibition of the Endogenous GIP Response With a GIP Receptor Antagonist (GA-3)

Acronym: GA-3

Important dates

Study start
2017
Primary completion
2017
Study completion
2017
First posted
Apr 28, 2017
Registry last updated
Nov 1, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.